What I was referring to is that there's typically no need to provide additional information for adverse reactions that we already know enough about. We already know how to deal with these interactions, so just providing more reports on the same reactions will not add to the body of knowledge for health care professionals and consumers on how to deal with these reactions. Then if we have this avalanche of data, it will be difficult to sieve through that data to identify the reactions that are actually very significant--new or poorly documented reactions to existing medications, as well as reactions to new medications.
To answer your question, I'm not sure providing more information on a body of knowledge that is already large will provide any additional--